Vivos Inc. Gets FDA Nod for Human Trials of RadioGel Cancer Therapy

Vivos Inc. has secured FDA approval for an Investigational Device Exemption, allowing it to commence a first-in-human clinical study for RadioGel®. This innovative yttrium-90-based injectable hydrogel aims to provide targeted treatment for cancerous tumors. The initial study will focus on non-resectable papillary thyroid carcinoma at the Mayo Clinic, representing a significant step in its development.